Related Experiment Video

Updated: Jun 12, 2026

Isolated Pancreatic Islet Treatment and Apoptosis Measurement
09:36

Isolated Pancreatic Islet Treatment and Apoptosis Measurement

Published on: May 2, 2025

Small-Molecule Suppressors of Cytokine-Induced beta-Cell Apoptosis

Danny Hung-Chieh Chou, Nicole E Bodycombe, Hyman A Carrinski

    ACS Chemical Biology
    |June 17, 2010
    PubMed

    Insights

    Researchers screened small molecules to prevent pancreatic beta-cell apoptosis, a key event in type-1 diabetes. Two compounds protected beta cells from cytokine-induced damage, offering potential therapeutic strategies.

    Area of Science:

    • Biochemistry
    • Immunology
    • Endocrinology

    Background:

    • Pancreatic beta-cell apoptosis is central to type-1 diabetes pathogenesis.
    • Developing small molecules to prevent this apoptosis offers therapeutic potential.

    Discussion:

    • A phenotypic cell-based assay screened 2,240 small molecules for their ability to prevent cytokine-induced beta-cell apoptosis.
    • Compounds were assessed using cellular ATP levels, caspase-3 activity, and nitrite production.

    Key Insights:

    • Glucocorticoids, pyrazole derivatives, and GSK-3beta inhibitors were among top-scoring compounds.
    • Two novel compounds enhanced ATP levels, reduced apoptosis markers, and improved insulin secretion.
    • These molecules show promise in protecting beta cells from autoimmune attack.

    Outlook:

    • The identified small molecules represent potential therapeutic candidates for early-stage type-1 diabetes.
    • Further research can explore these compounds for clinical application in preventing autoimmune diabetes.

    More Related Videos

    Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

    Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

    Published on: January 22, 2019

    Methods to Assess Beta Cell Death Mediated by Cytotoxic T Lymphocytes12:12

    Methods to Assess Beta Cell Death Mediated by Cytotoxic T Lymphocytes

    Published on: June 16, 2011

    Related Concept Videos

    The JAK-STAT Signaling Pathway01:20

    The JAK-STAT Signaling Pathway

    Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
    The Extrinsic Apoptotic Pathway01:17

    The Extrinsic Apoptotic Pathway

    The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
    Glucagon-like Receptor Agonists01:24

    Glucagon-like Receptor Agonists

    Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
    GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
    TGF - β Signaling Pathway01:16

    TGF - β Signaling Pathway

    The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
    Receptor Downregulation in MVBs01:15

    Receptor Downregulation in MVBs

    Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
    The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
    Dipeptidyl Peptidase 4 Inhibitors01:23

    Dipeptidyl Peptidase 4 Inhibitors

    Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...